Rorze (6323) · InitiativeRestated
Expansion into the Life Sciences Market through a Chinese Joint Venture
First written in FY2019. 1 of 2 entries say "Restated". Latest entry: FY2023.
2entries
5years
0from disclosures
How it moved
Same theme, other companies
Expansion into the Life Sciences Market through a Chinese Joint VentureA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2023RestatedAnnual report
「In the Life Science business, shipment delays and other effects of COVID-19 are expected to be resolved. The Company will coordinate with its affiliates and pursue sales promotion activities targeting China.」
The company has indicated a policy of continuing cooperation with affiliated companies and sales promotion activities targeting China in the Chinese life sciences market. - FY2019First statedAnnual report
「RORZE ReMed Lifescience Co.,Ltd. is a joint venture established in Shanghai, China, in September 2018 to promote the life sciences business in China, with Shanghai Ruitai Biotechnology Co., Ltd. holding a 51% stake and RORZE TECHNOLOGY TRADING CO.,LTD. holding a 49% stake.」
The company established a joint venture in Shanghai, China, creating a new structure for expanding its life sciences business into the Chinese market.